The Pharmaceutical Industry: The Risks & Rewards

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

  • VIDEO TEXT

Nov. 27 (Bloomberg) –- Bloomberg’s Manus Cranny reports on the outlook for the pharmaceutical industry in our Year Ahead 2014 series. He speaks to Anna Edwards and Mark Barton on Bloomberg Television’s “Countdown.” (Source: Bloomberg)

Series.

Where are the risks and rewards?

There is no shock when it comes to food and drugs.

Though be more rewards at moderate risks.

0-- and moderate risks.

When it comes to moderate risk or low risk, the blockbuster drugs, meet the blockbuster boys and girls.

Too early?

Okay.

[laughter] they have a leukemia drug.

There is antibody research for multiple sclerosis, sanofi.

And johnson & johnson, they have cancer drugs that were given rapid approval by the fda.

The blockbuster drug is $1 billion.

Those of the blockbusters coming on board.

They're still about 50 billion coming off patent protection going into 2014. all most 15% of that -- people -- summer under the least pressure.

-- some are under the least pressure.

Let's talk about the consolidation in the rate of which we see companies doing deals.

This is where you look for synergies.

Diabetes seems to be on top of it.

You have got -- pricing in america, five-year high.

Not so in europe.

Of course, pfizer has done $40 billion of buyback.

40 million bucks.

And there is ongoing investigation into china.

However continue to affect the drug industry?

Rehabilitation and get people to trust you again.

You will see sales rise 10-15%. of course, it is about engaging with the chinese.

They are not going away.

Manus cranny with their prescription.

I like it.

Say it again.

A prescription for 2014. prince william and prince

This text has been automatically generated. It may not be 100% accurate.

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change